Trillium Therapeutics, Inc. announced that it has dosed the first TP53-mutated acute myeloid leukemia patient with TTI-622, an investigational checkpoint inhibitor of the innate immune system, in combination with azacitidine.
[Trillium Therapeutics, Inc.]
7992332
{7992332:nan}
apa
50
1
165485
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
